IMPORTANCE To date, there is no diagnostic test for Kawasaki disease (KD). Diagnosis is based on clinical features shared with other febrile conditions, frequently resulting in delayed or missed treatment and an increased risk of coronary artery aneurysms. OBJECTIVE To identify a whole-blood gene expression signature that distinguishes children with KD in the first week of illness from other febrile conditions. DESIGN, SETTING, AND PARTICIPANTS The case-control study comprised a discovery group that included a training and test set and a validation group of children with KD or comparator febrile illness. The setting was pediatric centers in the United Kingdom, Spain, the Netherlands, and the United States. The training and test discovery group comprised 404 children with infectious and inflammatory conditions (78 KD, 84 other inflammatory diseases, and 242 bacterial or viral infections) and 55 healthy controls. The independent validation group comprised 102 patients with KD, including 72 in the first 7 days of illness, and 130 febrile controls. The study dates were MAIN OUTCOMES AND MEASURES Whole-blood gene expression was evaluated using microarrays, and minimal transcript sets distinguishing KD were identified using a novel variable selection method (parallel regularized regression model search). The ability of transcript signatures (implemented as disease risk scores) to discriminate KD cases from controls was assessed by area under the curve (AUC), sensitivity, and specificity at the optimal cut point according to the Youden index. RESULTS Among 404 patients in the discovery set, there were 78 with KD (median age, 27 months; 55.1% male) and 326 febrile controls (median age, 37 months; 56.4% male). Among 202 patients in the validation set, there were 72 with KD (median age, 34 months; 62.5% male) and 130 febrile controls (median age, 17 months; 56.9% male). A 13-transcript signature identified in the discovery training set distinguished KD from other infectious and inflammatory conditions in the discovery test set, with AUC of 96.2% (95% CI, 92.5%-99.9%), sensitivity of 81.7% (95% CI, 60.0%-94.8%), and specificity of 92.1% (95% CI, 84.0%-97.0%). In the validation set, the signature distinguished KD from febrile controls, with AUC of 94.6% (95% CI, 91.3%-98.0%), sensitivity of 85.9% (95% CI, 76.8%-92.6%), and specificity of 89.1% (95% CI, 83.0%-93.7%). The signature was applied to clinically defined categories of definite, highly probable, and possible KD, resulting in AUCs of 98.1% (95% CI, 94.5%-100%), 96.3% (95% CI, 93.3%-99.4%), and 70.0% (95% CI, 53.4%-86.6%), respectively, mirroring certainty of clinical diagnosis.
K awasaki disease (KD) is an acute inflammatory disorder predominantly seen in young children. Since it was first described in Japan, KD has emerged as the most common cause of acquired heart disease, with an incidence in children younger than years ranging from cases per in Japan, to to cases per in other Asian countries,to to cases per in Europe and the United States, respectively. What makes KD of such concern is its association with vasculitis, affecting predominantly the coronary arteries, which results in coronary artery aneurysms (CAAs) in up to % of untreated children. Death from myocardial infarction may occur due to thrombotic occlusion of the aneurysms or from the later development of stenotic lesions due to vascular remodeling in the damaged artery. Long-term outcome studies , of children with giant CAAs indicate a worrisome prognosis, with more than % needing revascularization or experiencing myocardial infarction within a -year period.
Treatment with intravenous immunoglobulin (IVIG) and, for those who do not respond, additional IVIG or other antiinflammatory agents, such as corticosteroids and infliximab, is effective in abrogating the inflammatory process and reduces the risk of CAAs to % to %. Because KD is difficult to distinguish from other common febrile conditions, many children with KD are not diagnosed and treated early enough to prevent development of CAAs. Furthermore, patients who do not fulfill the clinical criteria for diagnosing KD (so-called incomplete KD) may experience CAAs. Delayed diagnosis is a consistent risk factor for development of CAAs, and treatment is often commenced only when coronary dilatation is already demonstrated on echocardiography.
The symptoms of KD are similar to those of several other childhood febrile illnesses, including staphylococcal and streptococcal toxic shock syndromes, measles and other viral illnesses (eg, adenovirus infection, Rocky Mountain spotted fever), and childhood inflammatory diseases, leading to diagnostic difficulty and thus delay in diagnosis and treatment. Guidelines have been developed to facilitate diagnosis based on clinical signs and symptoms, echocardiography, and laboratory variables, but there remains an urgent need for an accurate test to distinguish KD from other conditions causing prolonged fever in children.
In the era of precision medicine, diagnosis of many conditions previously based on clinical features alone is being replaced by diagnosis based on molecular pathology. Host blood gene expression signatures have been shown to identify several specific infectious and inflammatory diseases, including tuberculosis, bacterial and viral infections, , and systemic lupus erythematosus. Support for a diagnostic approach to KD based on gene expression signatures comes from identification of microRNA biomarkers in KD, , although existing studies are limited by the range of comparator patients or a need to extract RNA from exosomes. We explored use of whole-blood gene expression patterns to distinguish KD from other childhood infectious and inflammatory conditions. We present a gene expression signature, discovered and validated in independent patient groups, that distinguishes KD from a range of bacterial, viral, and inflammatory illnesses. 
Patient Study Groups
The differential diagnosis for KD includes multiple infectious and inflammatory conditions. Therefore, in this case-control study, we established a discovery group of children with KD and a range of other infectious and inflammatory diseases with clinical signs, inflammatory markers, and duration of fever overlapping KD. , and data analysis took place from January , , to December , . Children with KD represented a combination of those seen directly in emergency departments and patients referred from regional centers. Our study included only patients recruited before initiation of IVIG for treatment. For discovery of a diagnostic signature, we included patients with KD in the first days of illness because we aimed to develop a test for use early in the illness before coronary artery damage occurs. However, to explore the performance of the signature at all stages of illness, we included patients up to day of their illness in the validation study.
Febrile controls whose duration of illness before hospital presentation varied were recruited, with blood samples collected as soon as possible after presentation and before clinical diagnosis was confirmed. Febrile controls were assigned to diagnostic groups using predefined criteria once the results of all investigations were available (Figure and eMethods in the Supplement). Children with comorbidities likely to influence gene expression, such as immunosuppressive treatments, were excluded. We included comparator groups of children seen with inflammatory illness, including juvenile idiopathic arthritis and Henoch-Schönlein purpura. Comparison of the duration of illness, inflammatory markers. and demographics between patients with KD and febrile controls is summarized in Table . Patients in the validation study group were similarly recruited as part of biomarker studies of febrile children seen in the hospital and requiring blood tests, as described previously. , Healthy control children with no recent history of fever or immunization were recruited alongside patients with KD and febrile control patients in the discovery and validation studies. Data from healthy controls were used to standardize data obtained in different microarray experiments but were not used to evaluate the performance of the signature.
KD Case Definition
Kawasaki disease was diagnosed on the basis of the American Heart Association criteria, with -dimensional echocardiography performed soon after presentation ( and weeks after onset). Patients with fewer than of the classic criteria (bilateral nonpurulent conjunctivitis, oral mucosal changes, peripheral extremity changes, rash, and cervical lymphadenopathy > . cm) were included as having incomplete KD if the maximum coronary artery z score (Zmax) (standard deviation units from the mean internal diameter normalized for body surface area) at any time during the illness for the left anterior descending or right coronary arteries was . or higher or if the patients satisfied the algorithm for incomplete KD in the American Heart Association guidelines. Patients were classified as having normal (Zmax < . ), small (Zmax . to < . ), or large (Zmax ≥ . ) CAAs. Because of interoperator variability in coronary artery dimensions, we set a high (Zmax ≥ . ) threshold to define patients with confirmed aneurysms and thus definite diagnosis of KD. 
Yes No
The diagnostic algorithm demonstrates the method of assigning patients to diagnostic groups. AHA indicates American Heart Association; CAA, coronary artery aneurysm; CRP, C-reactive protein; HSP, Henoch-Schönlein purpura; JIA, juvenile idiopathic arthritis; and KD, Kawasaki disease. To convert C-reactive protein level to nanomoles per liter, multiply by 9.524; to convert neutrophil count to ×10 9 /L, multiply by 0.001.
Further Classification of KD by Diagnostic Certainty
Because there is no gold standard for diagnosis, some patients may meet the criteria for KD but have other conditions. Therefore, we further categorized patients with KD in the validation study group based on certainty of clinical diagnosis. All clinical records, laboratory results, echocardiogram reports, response to treatment, and follow-up were reviewed by an independent pediatric infectious disease specialist and expert on KD (M.P.G.) masked to the analysis. Patients with documented CAAs (Zmax ≥ . ) persisting weeks after onset were considered to have definite KD because there is no other known self-resolving inflammatory illness in childhood that leads to CAAs. The remaining patients (all of whom were treated with IVIG for suspected KD) were classified as having highly probable, possible, or unlikely KD by the expert reviewer. This review identified no unlikely KD cases.
Febrile Control Children With Infection or Other Inflammatory Syndromes
Children seen with febrile illnesses were recorded as having definite bacterial infection, definite viral infection, sus-pected bacterial or viral infection, juvenile idiopathic arthritis, or Henoch-Schönlein purpura. The criteria shown in Figure  and described in eMethods in the Supplement were used to make this determination.
Oversight and Conduct of the Study
Patients were categorized into disease groups (Figure ) after evaluation of all results by independent clinicians not involved in the patients' care (J.A.H., A.M.B., J.T.K., M.P.G., and J.C.B.). All blood samples were anonymized, and transcriptomic data sets were analyzed only after clinical assignments were finalized and dispatched for independent verification (eMethods in the Supplement).
Discovery and Validation of the Gene Expression Signature
The overall study design and signature discovery pipeline are shown in Figure . Whole blood was collected at the time of recruitment into blood RNA tubes (PAXgene; PreAnalytiX), frozen, extracted, and analyzed on arrays (HumanHT-version . BeadChip; Illumina). An earlier array (HumanHT-version . BeadChip; Illumina) with 
SI conversation factors:
To convert C-reactive protein level to nanomoles per liter, multiply by 9.524; neutrophil count to ×10 9 /L, multiply by 0.001; platelet count to ×10 9 /L, multiply by 1.0; and white blood cell count to ×10 9 /L, multiply by 0.001. a There were no significant differences between patients with Kawasaki disease in the discovery and validation sets. largely overlapping probes was used in a subset of the validation study group. Details of laboratory methods are provided in eMethods in the Supplement.
Statistical Analysis
Transcript Signature Discovery Analysis of the transcriptomic data was conducted with statistical software (R, version . . ; R Foundation for Statistical Computing). As shown in Figure , the discovery study group was randomly divided into an % training set and a % test set. The signature was identified in the training set and validated in the test set and in the validation study group, established using previously reported acute and convalescent patients with KD and acute bacterial and viral patients (eMethods in the Supplement). After quality control and filtering (eMethods in the Supplement), significantly differentially expressed transcripts in patients with KD compared with all other diseases were identified in the training set.
Small Signature Discovery Using Parallel Regularized Regression Model Search
A range of statistical methods are available to identify signatures from significantly differentially expressed transcripts, including least absolute shrinkage and selection operator (LASSO) and elastic net. However, these approaches produce large signatures that may not be easy to translate into a bedside diagnostic test. Therefore, we developed a novel variable selection method, parallel regularized regression model search, that identifies and ranks transcript signatures on the basis of their least number of transcripts and highest accuracy in discrimination (eMethods in the Supplement). The method first evaluates all possible -and -transcript models distinguishing KD from comparator diseases based on all significantly differentially expressed transcripts and takes the best-fitting -transcript models to the next round, when a further transcript is added to the model and all combinations are again evaluated. The process continues with the incremental addition of further transcript at a time to the best models. The optimal signature for a given number of transcripts (model size) was selected after ranking each model by its Watanabe-Akaike information criterion, which is a Bayesian estimate of the out-of-sample error. The optimal model size was determined by cross-validation.
Disease Risk Score and Assessment of Model Accuracy
We applied the previously reported disease risk score (DRS) method that assigns individual disease risk based on the transcripts in the diagnostic signature. The DRS combines the fluorescence intensity of upregulated transcripts and subtracts the combined fluorescence intensity of downregulated transcripts and might facilitate development of tests from complex signatures. Healthy controls were used in model building but were excluded from estimates of model accuracy, assessed by area under the curve (AUC), sensitivity, and specificity at the optimal cut point according to the Youden index.
Results
The numbers of patients in each diagnostic category are shown in Figure . Clinical and demographic features of patients with KD and febrile controls are summarized in Table , with 
Identification of Minimal Transcript Signatures
In total, transcripts passed quality control and were significantly differentially expressed between KD and all other diseases and healthy controls (defined as log fold change > in KD vs at least of the comparator groups). To identify small signatures suitable for developing as a diagnostic test, we next undertook variable selection using parallel regularized regression model search. This approach identified a -transcript signature (Table ) that 
Signature Performance in Validation Set

Discussion
We identified a -transcript signature that distinguishes patients with KD from patients with bacterial, viral, and inflammatory illnesses. The high sensitivity and specificity of this signature for early diagnosis of KD suggests that it might form the basis of a diagnostic test. Our findings herein extend previous gene expression studies ,in KD that focused on immunopathogenesis. The diagnosis of KD now relies on the presence of of the characteristic clinical criteria. Fewer criteria are accepted if coronary artery abnormalities (dilatation or aneurysms) are detected on echocardiography. Children with incomplete KD who do not fulfil the classic diagnostic criteria but have prolonged fever and inflammation are at an increased risk of developing CAAs. One reason for the greater risk of CAAs in incomplete KD is the delayed diagnosis that often occurs in patients lacking all clinical features. Because the clinical features of KD overlap those of many other common childhood conditions, treatment with IVIG may be delayed while awaiting exclusion of other conditions. Conversely, because the diagnosis of KD is considered in the differential diagnosis of many childhood febrile illnesses and because the consequences of delayed treatment may be severe, overtreatment with IVIG or immunosuppressant second-line treatments may occur. A diagnostic test that accurately distinguishes KD from other infectious and inflammatory processes would be a significant advance in management of the disorder, reduce unnecessary investigations and inappropriate treatments, and enable earlier treatment with IVIG and other anti-inflammatory agents.
In establishing our discovery and validation study groups, we aimed to include a wide range of disorders with features overlapping those of KD, including both infectious and inflammatory diseases. The signature that we have identified distinguished KD from a wide range of other conditions with similar duration of fever and overlapping levels of inflammation. Because KD is diagnosed based on a constellation of clinical features and because there is no gold standard for diagnosis, evaluation of biomarker test results is difficult. Any cohort of children treated with IVIG for presumed KD is likely to include some patients with non-KD illness but with similar features. To evaluate the correspondence of the KD DRS with levels of diagnostic certainty, we categorized patients in the validation set as having definite, highly probable, or possible KD based on independent review of the clinical data. We observed a higher sensitivity and specificity of our signature in the definite and highly probable KD groups than in the possible KD group. Regarding the transcripts in the signature (Table ) , expression was lower in patients with KD compared with the non-KD group for of the transcripts. Of these, S P, previously reported to have increased expression in acute KD relative to convalescence or viral infections, , was most abundant in patients with bacterial infection. The IFI gene has been reported to be upregulated in children with viral compared with bacterial infections and autoimmune diseases, , consistent with reduced expression of genes induced by type interferons reported in acute KD vs adenovirus infection. CD is a transmembrane receptor expressed in macrophages and monocytes involved in bacterial clearance during acute infection. A network analysis of the signature using pathway analysis (Ingenuity Pathways Analysis; Ingenuity Systems) revealed that of the transcripts in the signature were connected in a network around a central hub of tumor necrosis factor and interleukin (eFigure in the Supplement).
Strengths and Limitations
We recognize both strengths and limitations in our study. First, the epidemiology of KD varies globally by ethnicity. Although we included patients with a mix of ethnicities in both discovery and validation cohorts, further studies are required to establish the performance of the signature in other geographic populations. Second, in the validation experiment, data from different Illumina microarray versions and studies were combined using the ComBat algorithm to achieve normalization. This normalization may reduce both experimental and biological sources of variability between data sets; consequently, the accuracy (AUC) of the signature in the validation set may be an underestimate. Conversely, although we showed that the ComBat algorithm success-fully normalized the data sets, residual batch associations may have falsely increased the performance of the signature. Third, to develop a signature applicable in a wide range of febrile conditions, we discovered the signature through comparison of KD cases with a wide range of febrile controls with a spectrum of KD diagnosis likelihoods. This potentially biased the test toward better discriminatory value than might be applicable in the clinical setting. Fourth, we discovered the signature using patients with KD in the first days of illness, with the aim of identifying a test for use early in the disease to enable treatment before coronary injury has occurred. Because the performance of the signature was lower in patients with KD seen after the seventh day, further work is required to establish the optimal signature for diagnosis in patients with KD with late presentation.
Conclusions
The results of our study suggest that KD can be distinguished from the range of infectious and inflammatory conditions with which it is often clinically confused using transcripts in blood. Development of a test based on this gene expression signature is made more achievable because of the small number of transcripts in our signature and the rapidly evolving technologies for detecting nucleic acids. A diagnostic test would be a major advance allowing earlier treatment and thus prevention of cardiac complications of this serious childhood disease. Our findings represent a step toward better diagnosis of diseases based on molecular signatures rather than the clinical criteria and are relevant to many other clinical syndromes. 
Diagnostic process in febrile controls
Patients had a diagnostic work-up as directed by the clinical team, including blood count, blood chemistry, Creactive protein (CRP), blood urine and throat swab cultures; cerebrospinal fluid analysis and chest radiographs were performed where appropriate. Multiplex PCR was used to detect common respiratory viruses in nasopharyngeal aspirates or throat swabs, and common viruses in blood. Once the results of all investigations were available, patients were assigned to diagnostic groups using predefined criteria (Figure 1 ), as follows:
Bacterial infection: Patients assigned to the bacterial pathogen group had a bacterial pathogen (gram-positive coccus or gram-negative bacillus) identified by culture or by molecular techniques in a sample from a sterile site (blood, CSF, pleural space, joint, urine), and a clinical syndrome in keeping with the identified bacterial species. This group included patients with and without viral co-infection. Children diagnosed with other bacterial infections (for instance mycoplasma, pertussis, mycobacteria) were not included in this group. No threshold for inflammatory markers was set for this group, as identification of bacteria in a sterile-site sample was taken as conclusive evidence for a confirmed bacterial infection.
Viral infection:
Patients in the viral infection group had an identified virus, a clinical syndrome in keeping with viral infection, and no microbiological or clinical features of bacterial disease. In order to avoid inclusion of children with occult bacterial infection in the viral group, children with raised inflammatory markers were excluded. A maximum threshold was set at CRP of 60mg/L, and neutrophil count of 12 x 10 9 /L. Among the 94 children, the most frequent pathogens were RSV (27 children), influenza A/B and adenovirus (23 children each).
Uncertain bacterial or viral infection: When children with an acute febrile illness and features of infection could not be assigned confidently to one of the above groups, they were labelled as 'Uncertain Bacterial or Viral'. Children in this group had inconclusive features of bacterial or viral infection, negative microbiological findings or absent virological investigations, a syndrome inconsistent with their microbiological findings, inflammatory markers inconsistent with other clinical features of their illness, or insufficient clinical data for confident coding in another group. Patients in this group did not have bacterial infection detected at a sterile site, and some patients did have detectable virus.
Other inflammatory syndromes: a) Henoch-Schönlein purpura (HSP) was diagnosed in children presenting with palpable purpura, typically over the buttocks and extensor surfaces in association with abdominal pain, arthralgia or renal abnormalities (hematuria and proteinuria); b) Juvenile idiopathic arthritis (JIA) was defined according to International League of Associations for Rheumatology 1 . Patients with JIA included i) treatmentnaïve and ii) active-exacerbation/smouldering. © Wright VJ. JAMA Pediatrics.
that maximizes the distance to the identity line (maximum of (sensitivities + specificities)) 9 . The same threshold was used in accuracy calculations for the validation data.
Confidence intervals (CI) for sensitivity and specificity were calculated using Jeffrey's method. Jeffrey's method is derived from a Bayesian perspective in which the underlying proportion of interest is assigned the non-informative Jeffrey's reference prior: Beta( ½, ½ ) 10 . Thus, sensitivity 95% CIs are derived from the 2.5% and 97.5% quantiles of a Beta (p+½, q+½) distribution, where p is the number of true positives and q is the number of false negatives. The network was generated using Ingenuity Pathways Analysis. 12 of the 13 transcripts were mapped to the database. This network, containing 7 focus molecules was the top network in the analysis. Each molecule is coloured according to the direction of expression in KD. Unbroken lines indicate direct interaction, dashed lines indicate indirect interaction.
The legend to the network is located at http://ingenuity.force.com/ipa/articles/Feature_Description/Legend.
